Molecular Formula | C35H36ClNO3S |
Molar Mass | 586.18 |
Density | 1.272±0.06 g/cm3(Predicted) |
Melting Point | 145-148 °C(Solv: toluene (108-88-3); methanol (67-56-1)) |
Boling Point | 750.5±60.0 °C(Predicted) |
Flash Point | 407.7°C |
Vapor Presure | 1.17E-23mmHg at 25°C |
pKa | 4.76±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.677 |
In vitro study | Montelukast (5 μM; 1 h) inhibits APAP-induced cell damage. |
3 [2-(7-monochloro-2-quinolyl) vinyl] Benzaldehyde was dissolved in toluene and a toluene/THF solution of vinyl magnesium bromide was slowly added at 0 °c. The obtained product and LiOAc/2 H2 0, LiCl, Pd( OAc)2 and O-bromobenzoic acid methyl ester were suspended in DMF, the reaction gave methyl 2-[3-[3-[2-(7-chloro-2-quinolinyl) vinyl] phenyl l-3-carbonylpropyl] benzoate. The material was reduced with boride. Further, methylation and etherification are carried out, and addition of dihydropyrrole is carried out, tert-butyl dimethyl silicon is removed under the action of tetrabutylammonium fluoride, and methanesulfonylation is carried out with methanesulfonyl chloride to obtain methanesulfonyl product. The reaction of the methanesulfonylated product with methyl 1-(acetylthiomethyl) cyclopropane acetate yields montelukast via hydrolysis. Montelukast was dissolved in ethanol and an equal amount of sodium hydroxide was added to obtain the monosodium salt of montelukast.
developed by Merck & Co. Inc., USA, was launched in Mexico in 997. Antiasthmatic drugs. Selective leukotriene D4 receptor antagonists.